Summit-logo-RGB.png
Summit Therapeutics Announces Commencement of $100 Million Rights Offering
18. Juli 2022 16:05 ET | Summit Therapeutics Inc.
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the...
Summit-logo-RGB.png
Summit Therapeutics Provides Update on Ridinilazole
14. Juli 2022 08:30 ET | Summit Therapeutics Inc.
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of...
Summit-logo-RGB.png
Summit Therapeutics Announces $100 Million Rights Offering
22. Juni 2022 16:30 ET | Summit Therapeutics Inc.
Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights...
Summit-logo-RGB.png
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
03. Juni 2022 08:30 ET | Summit Therapeutics Inc.
Menlo Park, CA, June 03, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting,...
Summit-logo-RGB.png
Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer
01. Juni 2022 08:30 ET | Summit Therapeutics Inc.
Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately. ...
Summit-logo-RGB.png
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
11. Mai 2022 16:30 ET | Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...
Summit-logo-RGB.png
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
17. März 2022 16:14 ET | Summit Therapeutics Inc.
Cambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its...
Summit-logo-RGB.png
Summit Therapeutics Announces Postponement of Its Planned Rights Offering
09. Februar 2022 08:00 ET | Summit Therapeutics Inc.
Cambridge, Massachusetts, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced the postponement of its previously announced rights...
Summit-logo-RGB.png
Summit Therapeutics Announces Rights Offering
25. Januar 2022 07:30 ET | Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a...
Summit-logo-RGB.png
Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
10. Januar 2022 08:00 ET | Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the...